Parenteral Delivery of Peptides and Proteins - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 602

[229] Takenaka H, Fujioka K, Takada Y. New formulations of interferon. In: Marshak D, Liu
D, editors. Therapeutic peptides and proteins: formulation, delivery and targeting. Cold
Spring, MD: Cold Spring Harbor Laboratory; 1989. p. 37-40.
[230] Mariette B, Coudane J, Vert M, Gautier JC, Moneton P. Release of the GRF29NH(2)
analog of human GRF44NH(2) from a PLA/GA matrix. J Control Release 1993;24:
237-46.
[231] Bergers JJ, Otter WD, Crommelin DJA. Vesicles for tumour-associated antigen presen-
tation to induce protective immunity: preparation, characterization and enhancement of
the immune response by immunomodulators. J Control Release 1994;29:317-27.
[232] Roseanu A, Florian PE, Moisei M, Sima LE, Evans RW, Trif M. Liposomalization of
lactoferrin enhanced its anti-tumoral effects on melanoma cells. BioMetals 2010;23:
485-92.
[233] Langston MV, Ramprasad MP, Kararli TT, Galluppi GR, Katre NV. Modulation of the
sustained delivery of myelopoietin (Leridistim) encapsulated in multivesicular lipo-
somes (DepoFoam). J Control Release 2003;89:87-99.
[234] Katayama K, Kato Y, Onishi H, Nagai T, Machida Y. Double liposomes: hypoglycemic
effects of liposomal insulin on normal rats. Drug Dev Ind Pharm 2003;29:725-31.
[235] Lambros MP, Abbas SA, Dunn ST, Raja T, Pento T. Targeting hepatocytes with liposo-
mal interferon-: effect on metallothionein gene induction. Res Commun Mol Pathol
Pharmacol 2002;112:50-8.
[236] Mohanraj VJ, Barnes TJ, Prestidge CA. Silica nanoparticle coated liposomes: a new
type of hybrid nanocapsule for proteins. Int J Pharm 2010;392:285-93.
[237] Tan ML, Choong PF, Dass CR. Recent developments in liposomes, microparticles and
nanoparticles for protein and peptide drug delivery. Peptides 2010;31:184-93.
[238] Glavas-Dodov M, Fredro-Kumbaradzi E, Goracinova K, Simonoska M, Calis S,
Trajkovic-Jolevska S, et al. The effects of lyophilization on the stability of liposomes
containing 5-FU. Int J Pharm 2005;291:79-86.
[239] Schwendener RA, Lagocki PA, Rahman YE. The effects of charge and size on the inter-
action of unilamellar liposomes with macrophages. Biochim Biophys Acta 1984;772:
93-101.
[240] Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ. Monoclonal anti-
body to HER-2/neureceptor modulates repair of radiation-induced DNA damage and
enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
Cancer Res 1999;59:1347-55.
[241] Gunawan RC, Auguste DT. The role of antibody synergy and membrane fluidity in the
vascular targeting of immunoliposomes. Peptides 2010;31:184-93.
[242] Nissander UK, Steerenberg PA, Poppe H, Storm G, Jap PHK, Poels LG, et al. In vivo
targeting of OV-TL3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3)
in athymic nude mice. Cancer Res 1992;52:646-53.
[243] Kanaoka E, Takahashi K, Yoshikawa T, Jizomoto H, Nishihara Y, Hirano K. Continuous
release of interleukin-2 from liposomal IL-2 (mixture of interleukin-2 and lipo-
somes) after subcutaneous administration to mice. Drug Dev Ind Pharm 2003;29:
1149-53.
[244] van Slooten ML, Visser AJ, van Hoek A, Storm G, Crommelin DJ, Jiskoot W.
Conformational stability of human interferon- on association with and dissociation
from liposomes. J Pharm Sci 2000;89:1605-19.
[245] van Slooten ML, Boerman O, Romoren K, Kedar E, Crommelin DJ, Storm G. Liposomes
as sustained release system for human interferon-: biopharmaceutical aspects. Biochim
Biophys Acta 2001;1530:134-45.